Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-026742
Date:2023-04-29
Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
Original Submission Date:

Reporting Person:

DAVIS STEPHEN
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400 SAN DIEGO, CA 92130

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2023-04-29 M 15,625 a $0.00 116,103 direct
COMMON STOCK 2023-05-01 S 7,806 d $21.18 108,297 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
RESTRICTED STOCK UNITS 0.0 2023-04-29 deemed execution date M 15,625 (d) common stock 15,625 $0.00 0 direct
Footnotes
IDfootnote
f1 the sales reported in this form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
f2 each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
f3 the restricted stock units vest in four equal annual installments beginning april 29, 2020.
WhaleWisdom Logo

Elevate your investments